Gastrocalm

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrocalm

Quick Facts

Property Description
Active ingredient Metoclopramide
Form Tablet, Oral Solution, Injection
Pharmacological class Prokinetic Agent / Antiemetic Agent
Common use Regulating upper digestive motility
Origin Synthetic

Gastrocalm: Identity, Active Ingredient, and Pharmacological Class

Gastrocalm is a pharmaceutical preparation whose primary active ingredient is the synthetic compound Metoclopramide, a substituted benzamide derivative. The medicine is officially classified as both a prokinetic agent and an antiemetic agent. This dual classification is clinically recognized for addressing gastrointestinal discomfort.

The formulation is a single-ingredient product designed to influence both the central nervous system and the gastrointestinal tract. This distinctive dual activity allows Metoclopramide to coordinate digestive movement while suppressing the central signals that initiate vomiting, offering a broad scope of support compared to single-mechanism agents. For instance, the compound is often the chosen initial agent for restoring function in patients experiencing conditions that cause delayed stomach emptying.

What Type of Medicine is Metoclopramide and What Does it Generally Do?

Metoclopramide is fundamentally a gastrointestinal modifier that regulates motility, helping to restore normal rhythm and movement through the upper digestive tract. Its general purpose is to alleviate discomfort caused by slow gut movement and to control the physical urge to vomit.

Metoclopramide's effect as a Dopamine D2 receptor antagonist is essential to both its prokinetic and antiemetic properties. This action indicates that the compound actively restores and enhances the coordination of contractions in the upper gut, accelerating gastric emptying. Simultaneously, its direct action on the brain’s vomiting center reduces the feeling of nausea.

Dosage Forms and Routes of Administration

The active compound Metoclopramide is supplied in several distinct pharmaceutical presentations to ensure flexibility for patient administration. These dosage forms include solid oral preparations, such as the standard tablet and the Orally Disintegrating Tablet (ODT), as well as liquid forms. In clinical settings, the medicine is also available as a sterile solution for injection, which is administered via the parenteral route of administration, specifically intravenous (IV) or intramuscular (IM) injection. This range of forms ensures the compound can be delivered effectively regardless of the patient’s immediate digestive state.

Regulatory References

  1. Metoclopramide Drug Information (NIH/MedlinePlus)

What side effects are possible with Gastrocalm?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient, Metoclopramide, is characterized primarily by adverse reactions affecting the Nervous System and Psychiatric Disorders, as documented in government regulatory sources such as the FDA and EMA. These documents classify the possible side effects into frequency categories.

Reactions classified as Very Common include somnolence (drowsiness). Common effects may include diarrhea, asthenia (loss of strength), and Extrapyramidal Symptoms (EPS), such as difficulty sitting still (akathisia) and symptoms resembling Parkinson's disease (Parkinsonism).


Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights several serious adverse reactions. A Boxed Warning in U.S. documents emphasizes the risk of Tardive Dyskinesia (TD), a potentially irreversible involuntary movement disorder. The risk of TD is tied to long-term use and the cumulative dose; therefore, therapy is officially restricted to short durations.

Other serious risks include Neuroleptic Malignant Syndrome (NMS), which is very rare but life-threatening, and rare severe cardiovascular events, such as cardiac arrest and severe bradycardia, particularly associated with intravenous administration. Psychiatric risks include depression, which may involve suicidal ideation.


Population-Specific Considerations

Official safety information specifies that older adults are at a heightened risk for Tardive Dyskinesia. Dose adjustments are mandated for individuals with renal impairment (kidney function issues) and severe hepatic impairment (liver issues) to prevent drug accumulation and increased risk of adverse effects. Furthermore, the medicine is contraindicated in children younger than 1 year of age due to an increased risk of neurological reactions.

Overdose and Emergency Response

Gastrocalm (Metoclopramide) overdosage is documented in regulatory labeling primarily by its effects on the central nervous and blood systems. Officially documented manifestations include acute CNS effects such as drowsiness, disorientation, lethargy, and seizures (convulsions). The official profile also describes Extrapyramidal Reactions (EPS), which are characterized by uncontrolled movements, and the systemic toxicity of Methemoglobinemia.

Regulators emphasize that immediate medical attention must be sought in all cases of suspected overdose. Severe outcomes, including Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome, and Methemoglobinemia, require urgent intervention. The label mandates immediate discontinuation of the medicine if NMS symptoms are observed.

Management described in official documents focuses on symptomatic and supportive treatment. For Methemoglobinemia, Methylene blue can be used as a specific treatment. Extrapyramidal Reactions may be controlled with anticholinergic or antiparkinson drugs. It is noted that overdose symptoms are often self-limiting, typically resolving within 24 hours. However, regulatory information cautions that dialysis is not expected to be an effective method for drug removal. Special considerations are documented for neonates and children, who have reported risks of Methemoglobinemia and severe EPS following overdose.

Therapeutic Uses of Gastrocalm

What Gastrocalm Treats: Main Uses and Benefits

Gastrocalm is formulated to help provide symptom relief across several common digestive complaints. It is primarily used to assist in the management of symptoms associated with mild-to-moderate conditions affecting the gastrointestinal tract.

The medicine's main indications include temporary relief from heartburn, indigestion, and the discomfort of acid reflux. This makes it a common choice in scenarios where patients experience occasional post-meal burning sensations or general stomach upset. The core benefit is that it is intended to assist with patient comfort during acute episodes of gastric distress.

“Symptom management is key to supporting daily comfort.”

These types of preparations are commonly used for temporary relief of digestive symptoms. This is consistent with general information on non-prescription digestive aids.


Quick Fact: Relief for Stomach Upset

Regulatory References

  1. NIH MedlinePlus guidance on antacids

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility rules for Gastrocalm (Metoclopramide) as defined by regulatory bodies (e.g., FDA, EMA).


Eligibility Scope

Category Regulatory Statement
Populations for whom use is allowed Adults for approved short-term treatments like diabetic gastroparesis or specific types of nausea and vomiting.
Populations for whom use is contraindicated Patients with Gastrointestinal hemorrhage, mechanical obstruction, or perforation. Patients with Epilepsy or a known history of Tardive Dyskinesia (TD). Individuals with a confirmed or suspected Pheochromocytoma or known hypersensitivity to the drug.
Age-related eligibility rules Contraindicated in children less than 1 year of age. Use in patients aged 1–18 years is restricted to specific, second-line indications. Older adults may require a lower starting dosage due to increased sensitivity.
Condition-specific eligibility rules Eligibility is conditional in cases of moderate to severe Renal or Hepatic Impairment, requiring a mandatory dose reduction. Use should be avoided in patients with Parkinson’s disease or a prior history of depression.
Eligibility-related restrictions Therapy is generally limited to a maximum duration of 12 weeks (FDA) or 5 days (EMA) to reduce the risk of TD. Avoid concurrent use of other drugs likely to cause extrapyramidal reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gastrocalm is a product often containing Simethicone, a substance generally considered non-systemically absorbed and with limited known drug-to-drug interactions. However, a significant interaction has been documented with products used for thyroid hormone replacement.

Key Documented Interaction

Interacting Product Category Specific Medicines Listed Interaction Severity Mechanism/Effect
Thyroid Preparations Levothyroxine, Liothyronine, Liotrix, Thyroid Desiccated Moderate Decreased oral bioavailability of the thyroid medicine due to adsorption.

Interaction-Related Restriction

Concurrent use of Simethicone-containing products with thyroid replacement medicines is associated with a risk of reduced therapeutic effect of the thyroid medicine. To minimize this effect, a minimum separation of at least four (4) hours between the administration of the two products is typically recommended.

Other Potential Interactions

Combination products marketed under the 'Gastrocalm' name may also contain antacid ingredients (e.g., aluminum or magnesium salts). These antacids can affect the absorption of a wide range of oral medicines by changing the stomach’s acidity or by physically binding to them. This may necessitate monitoring or a staggered dosing schedule for many prescription drugs. Additionally, co-administration with products containing citrates may enhance the systemic absorption of aluminum, a concern for individuals with compromised kidney function. Patients are advised to consult official labeling for any combination product.

Mechanism of Action

How Gastrocalm Works: Mechanism of Action

Gastrocalm operates via a multi-modal pharmacodynamic mechanism targeting neurohumoral regulation and local luminal activity. The drug acts as an antagonist at specific muscarinic receptors on gastrointestinal smooth muscle and Dopamine D2 receptors in the enteric nervous system (ENS) and the central emetic center. This action dampens signaling that drives involuntary muscle contractions and suppresses signals originating from the central vomiting reflex, resulting in decreased frequency of visceral smooth muscle contractions.

Simultaneously, modulation of peripheral D2 and 5- HT4 serotonin receptors within the ENS accelerates propulsive peristalsis. This physiological modulation promotes accelerated gastric emptying and increased tone of the Lower Esophageal Sphincter (LES).

Additionally, the formulation includes components that stimulate the production of mucin, forming a viscous physical layer over the mucosal surface. Supplemental digestive enzymes exert extrinsic catalytic breakdown of complex macromolecules in the lumen. This dual local action alters the quantity of unhydrolyzed food passing into the lower tract, minimizing subsequent fermentation and excessive gas production.

Dosage and Administration Information

Gastrocalm (Metoclopramide) administration follows defined principles across its available forms: oral (tablets, solutions, ODT), intravenous (IV), and intramuscular (IM). The prescribed use is specific concerning dose, timing, and duration.

Oral immediate-release forms are directed to be taken 30 minutes before each meal and at bedtime. The standard dosing regimen for indications like Diabetic Gastroparesis is 10 mg four times daily, with the maximum recommended daily dose restricted to 40 mg. A fundamental administration rule for all immediate-release formulations is the mandatory 6-hour interval between any two administrations, a measure to ensure proper scheduling.

Treatment with this medicine is defined as short-term. The maximum established duration varies by indication; the duration for acute uses is limited to 5 days, while durations up to 12 weeks are utilized for Diabetic Gastroparesis.

Parenteral administration involves specific procedural handling: intravenous doses are administered as a slow bolus over a minimum of 1 to 3 minutes. Furthermore, a dose reduction is utilized for patients with moderate-to-severe renal impairment or severe hepatic impairment to account for reduced drug clearance.

Recent Clinical Evidence

Gastrocalm (Metoclopramide) has been evaluated across several clinical contexts, primarily through short-term randomized controlled trials (RCTs), systematic reviews, and meta-analyses. The research structure highlights what types of evidence exist for three primary areas of clinical evaluation.

Evidence for Delayed Stomach Emptying

Research for delayed stomach emptying in adults with diabetes has focused on short-term RCTs. These studies examined patient-reported outcomes, such as changes in nausea, vomiting, and fullness, alongside functional measures like the rate of stomach emptying. The evidence level for this indication is broadly categorized as Moderate. Symptom measurements in these studies were not always consistent with measured changes in the emptying rate.

Acute Use and Symptom Management

The evidence base for managing acute postoperative nausea and vomiting is extensive, primarily utilizing systematic reviews and meta-analyses of numerous RCTs. These studies monitored acute symptom changes and the need for immediate rescue medication within the first 24 hours. The evidence level for this indication is broadly categorized as High. Comparative evidence against certain other treatments reports mixed results.

Research has also explored the compound for the symptom management of acute migraine attacks. Studies monitored outcomes related to both headache pain intensity and associated nausea relief, with much of the available research relying on trials where the intravenous route of administration was observed. The evidence level for this indication is categorized as Moderate.

Research Gaps and Uncertainty

A common theme across the research landscape is the limitation of long-term data. Follow-up durations were limited in formal clinical trials, and there is a clear research gap regarding prolonged use. Studies also indicate that data for special populations, such as children and older adults, remain insufficient. This overall research framework for chronic use is limited, resulting in regulatory restrictions on the studied duration of administration.

Frequently Asked Questions (FAQ)

Common questions about Gastrocalm (FAQ)

Q: Is Gastrocalm similar to [Name of common over-the-counter drug]?

A: Gastrocalm’s primary active ingredient is officially classified as a prokinetic and antiemetic agent. Its mechanism is designed to help coordinate stomach movement and relieve nausea. This action is different from common over-the-counter products like antacids, which primarily work by neutralizing stomach acid, or simethicone, which helps break up gas. However, some combination products marketed as Gastrocalm may contain additional components like antacids.


Q: Why is Gastrocalm sometimes prescribed instead of other treatments?

A: Official information describes the active compound as having a distinctive dual activity that influences the movement of the upper digestive tract. This specific mechanism helps restore and enhance the coordination of stomach contractions. This unique action is a factor contributing to its selection for conditions where stomach motility is the primary concern.


Q: Is there any information about Gastrocalm interacting with blood pressure medication?

A: Official safety information recommends cautious use in individuals with high blood pressure, also known as hypertension. This caution is advised because the active compound has been shown to potentially induce the release of certain hormones that can elevate blood pressure. Reference to the official labeling describes any specific known interactions with blood pressure medications.


Q: Are there any food or drinks that should be limited while using Gastrocalm?

A: Regulatory guidance advises against drinking alcohol while using the active compound in Gastrocalm, as this combination can increase drowsiness and tiredness. Aside from alcohol, official documents generally do not list specific food or drink restrictions.


Q: Can Gastrocalm be used for general indigestion that is not severe?

A: The medicine is approved for specific, diagnosed conditions, such as delayed stomach emptying in diabetic adults, or acute nausea and vomiting. Its approved uses focus on specific, diagnosed conditions, and its role for general, unspecified indigestion is not the primary focus of the official label.


Q: Is it normal if I don't feel any immediate difference after taking Gastrocalm?

A: Studies examining delayed stomach emptying indicate that symptom changes were not always consistent with measured functional improvements in stomach emptying. Therefore, a noticeable, immediate feeling of difference may not always be observed.


Q: Has Gastrocalm been studied in children or teenagers?

A: Official documents state that use in patients aged 1 to 18 years is restricted to specific indications and is typically considered a second-line option. Official research documents indicate that data for special populations, including children and older adults, remain insufficient.


Q: Are there any non-prescription supplements that should not be taken with Gastrocalm?

A: Regulatory guidance suggests informing a healthcare professional about all non-prescription products you take, including herbal remedies or supplements, as there may be potential for interaction.


Q: Is Gastrocalm the type of medicine that stays in the body for a long time?

A: The medicine is absorbed quickly after administration, with peak levels generally reached in about one to two hours. Based on official pharmacokinetic data, the compound has a half-life of approximately 4 to 6 hours, indicating the body clears the medicine relatively quickly.


Q: Why do some people on forums say they take Gastrocalm 'as needed'?

A: While the medicine is prescribed for specific, scheduled regimens for certain conditions, patient information in some regions indicates the medication may be taken on an 'as needed' basis for acute symptoms like nausea or vomiting. The official prescribed regimen is to be followed when directed by a healthcare provider.


Q: Can Gastrocalm be used to manage heartburn at night?

A: Official information indicates the medicine is approved for the treatment of gastroesophageal reflux disease (GERD) and its associated symptoms, which include heartburn, in certain patients. Official administration guidelines include a dose to be taken at bedtime.


Q: Are there any specific patient groups where Gastrocalm studies have shown different results?

A: Research has found mixed results when comparing the active compound against certain other treatments for acute symptom management. Furthermore, studies indicate that data for special populations, such as children and older adults, remain insufficient to draw broad conclusions about different results in these groups.


Q: Is Gastrocalm meant for temporary relief or chronic management?

A: Regulatory documents define treatment with the active compound as short-term therapy. The maximum authorized duration is defined by regulatory bodies (e.g., up to 5 days in the EU or 12 weeks in the US). This short-term designation is related to concerns observed with prolonged use.


Q: Can women who are pregnant or breastfeeding use Gastrocalm?

A: Official risk summaries state that malformative risk with use in pregnant women is considered unlikely (AU TGA Category A). However, use is generally considered only when clearly needed. The active compound is known to be excreted into human milk, and its use during breastfeeding may be limited to a short duration with monitoring.


Q: Are there any known severe allergic reactions associated with Gastrocalm?

A: Official patient safety information notes that severe drug allergy symptoms, such as an extremely swollen face, difficulty breathing, or widespread itchy skin rashes, are rare but serious events. These symptoms require immediate medical attention should they occur.


Q: What is the regulatory classification of Gastrocalm (e.g., prescription only or OTC in some countries)?

A: In many countries, including the United States, the medicine whose active ingredient is Metoclopramide is generally available only with a healthcare professional’s prescription. Its classification varies by region, but it is typically not an over-the-counter (OTC) product.


Q: Can Gastrocalm be taken with vitamins or mineral supplements?

A: Regulatory guidance suggests informing a healthcare professional if you are taking any vitamins or mineral supplements. Regulatory guidance suggests informing a healthcare professional about all supplements, as there may be potential for interaction.


Q: Are there different brand names for the same active ingredient as Gastrocalm?

A: Yes. The active ingredient in Gastrocalm is Metoclopramide, which is marketed under several different brand names globally. Examples of these alternative names include Reglan, Maxolon, Gimoti, and Metozolv ODT.


Q: Are there reports of taste changes while taking Gastrocalm?

A: While taste changes, scientifically known as dysgeusia, are not typically listed among the common side effects, post-marketing surveillance data has examined this association. This indicates that a change in taste is a potential, though less common, observation with the active compound.


Q: Is it true that alcohol is prohibited while taking Gastrocalm?

A: Official patient information often advises against alcohol use, as combining the two may increase central nervous system depression, which can lead to excessive sleepiness or difficulty concentrating.

How should Gastrocalm be stored and disposed of?

How to Store and Dispose of Gastrocalm

The storage of Gastrocalm (Metoclopramide) is defined by strict regulatory requirements to maintain product stability and safety.

Storage Conditions

Gastrocalm tablets and oral solution must be stored at Controlled Room Temperature, which is between 68 F and 77 F (20 C and 25 C). The medication must be kept from freezing and protected from excess heat, moisture, and direct light. Always store Gastrocalm in its original container, tightly closed.

For household safety, the medicine must be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Gastrocalm should be discarded according to local regulations. Health authorities recommend using a local drug take-back program when available. If a take-back program is not accessible, the medicine should be mixed with an unappealing substance (like coffee grounds), sealed in a bag, and thrown into the household trash. Do not flush this medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrocalm found in:

A-Z Index: